NR1D1 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small molecule; not a steroid or peptide. |
| Primary targets | NR1D1 and NR1D2 | Also known as REV-ERBα and REV-ERBβ. |
| Studied routes | Intraperitoneal in rodents | Oral bioavailability in humans is not established. |
| Human approval | No approved therapeutic indication | No recognized clinical use. |
| Key uncertainty | Human physiological effects | Preclinical findings may not translate. |
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
A 1998 study was performed on NCAA football players during an 8-week spring training program. Those who took the ZMA capsules experienced greater increases in muscle strength. However, the study was funded by SNAC Systems Inc, which controls the trademark for ZMA. One of the study's authors, Victor Conte, has ownership equity in SNAC System Inc. In 2004, supplement company Cytodyne funded a study on 42 resistance-trained males using a product called Z-Mass PM that contained ZMA and additional ingredients Mucuna pruriens and polypodium vulgare. The study found that Z-Mass PM supplementation had no significant effects on total and free testosterone, IGF-1, growth hormone, cortisol, the ratio of cortisol to testosterone, or muscle and liver enzymes in response to training. No significant effects were observed in changes in strength, upper or lower body muscle endurance, or anaerobic sprint capacity. In another study done in 2006, a team of German scientists measured the effect of ZMA on testosterone levels. The study found that ZMA altered urine color due to increased secretion of zinc. It found no effect on testosterone levels.
Problems with mRNA stability have been identified in viral genomes, cancer cells, and various diseases. Research shows that many of these problems arise because of faulty ARE function. Deficiency of the ZFP36 family show that ZFP36 ARE binding proteins are critical regulators of T cell homeostasis and autoimmunity. Deficient mice have also indicated a protective role for ZFP36 ARE binding proteins via regulating cytokine levels in the thymic microenvironment, thereby preventing thymic involution. Additional potential problems have been listed below:
The plutonium present in spent nuclear fuel contains about 12% of 241Pu. Because it beta-decays to 241Am, 241Pu can be extracted and may be used to generate further 241Am. However, this process is rather slow: half of the original amount of 241Pu decays to 241Am after about 15 years, and the 241Am amount reaches a maximum after 70 years. The obtained 241Am can be used for generating heavier americium isotopes by further neutron capture inside a nuclear reactor. In a light water reactor (LWR), 79% of 241Am converts to 242Am and 10% to its nuclear isomer 242mAm:
Sources: en.wikipedia.org
Mohs surgery, developed in 1938 by general surgeon Frederic E. Mohs, is microscopically controlled surgery used to treat both common and rare types of skin cancer. During the surgery, after each removal of tissue and while the patient waits, the tissue is examined for cancer cells. That examination dictates the decision for additional tissue removal. Mohs surgery is the gold standard method for obtaining complete margin control during removal of a skin cancer (complete circumferential peripheral and deep margin assessment using frozen section histology). This method allows for the removal of skin cancer with a very narrow surgical margin and a high cure rate. The cure rate with Mohs surgery cited by most studies is between 97% and 99.8% for primary basal-cell carcinoma, the most common type of skin cancer. Mohs procedure is also used for squamous cell carcinoma, but with a lower cure rate. Recurrent basal-cell cancer has a lower cure rate with Mohs surgery, more in the range of 94%. It has been used in the removal of melanoma-in-situ (cure rate 77% to 98% depending on surgeon), and certain types of melanoma (cure rate 52%). Other indications for Mohs surgery include dermatofibrosarcoma protuberans, keratoacanthoma, spindle cell tumors, sebaceous carcinomas, microcystic adnexal carcinoma, merkel cell carcinoma, Paget's disease of the breast, atypical fibroxanthoma, and leiomyosarcoma. Because the Mohs procedure is micrographically controlled, it provides precise removal of the cancerous tissue, while healthy tissue is spared.
The post–Cold War era was marked by sustained economic prosperity in much of the Western world, particularly in the United States, alongside a broad wave of democratization across Latin America, Africa, and Central, South-East, and Eastern Europe. Sociologist Immanuel Wallerstein expresses a less triumphalist view, arguing that the end of the Cold War is a prelude to the breakdown of Pax Americana. In his Foreign Policy essay entitled, "The Eagle Has Crash Landed", Wallerstein argues, "The collapse of communism in effect signified the collapse of liberalism, removing the only ideological justification behind US hegemony, a justification tacitly supported by liberalism's ostensible ideological opponent".
As iced-tea mix As fermented mix without alcohol (vegetable or fruit juice) As a supplement for vegetable or fruit juices to intensify the sweet flavor, to increase the nutritional value, as well as to create a umami taste Light or dark hemp drink without alcohol similar to beer As a distilled hard liquor, such as hemp spirit As herb liqueur or bitter using alcohol and sugar in the production process As a mixer for alcoholic drinks such as cocktails As a brewing ingredient for hemp beer As a base for gluten-free beer Gluten-free hemp beer does not require malt or cereal mash and it is low in calories. Hemp as a close relative of hops provides the fine and bitter beer taste even without using any hops.
=== EC 2.1.2: Hydroxymethyl-, Formyl- and Related Transferases === EC 2.1.2.1: glycine hydroxymethyltransferase EC 2.1.2.2: phosphoribosylglycinamide formyltransferase 1 EC 2.1.2.3: phosphoribosylaminoimidazolecarboxamide formyltransferase EC 2.1.2.4: glycine formimidoyltransferase EC 2.1.2.5: glutamate formiminotransferase EC 2.1.2.6: deleted, included in EC 2.1.2.5 EC 2.1.2.7: D-alanine 2-hydroxymethyltransferase EC 2.1.2.8: deoxycytidylate 5-hydroxymethyltransferase EC 2.1.2.9: methionyl-tRNA formyltransferase EC 2.1.2.10: aminomethyltransferase EC 2.1.2.11: 3-methyl-2-oxobutanoate hydroxymethyltransferase EC 2.1.2.12: now EC 2.1.1.74 EC 2.1.2.13: UDP-4-amino-4-deoxy-L-arabinose formyltransferase EC 2.1.2.14: GDP-perosamine N-formyltransferase
Sources: en.wikipedia.org
=== Attenuance === Absorbance is a number that measures the attenuation of the transmitted radiant power in a material. Attenuation can be caused by the physical process of "absorption", but also reflection, scattering, and other physical processes. Absorbance of a material is approximately equal to its attenuance when both the absorbance is much less than 1 and the emittance of that material (not to be confused with radiant exitance or emissivity) is much less than the absorbance. Indeed,
=== Head and neck === Due to weakness of the muscles of facial expression and muscles of mastication, facial weakness may manifest as the inability to hold the mouth closed (the "hanging jaw sign") and as a snarling expression when attempting to smile. With drooping eyelids, facial weakness may make the individual appear sleepy or sad. Difficulty in holding the head upright may occur.
1993/729) Income Tax (Sub-contractors in the Construction Industry) Regulations 1993 (S.I. 1993/743) Income Tax (Employments) Regulations 1993 (S.I. 1993/744) Health and Safety (Miscellaneous Modifications) Regulations 1993 (S.I. 1993/745) Access to Health Records (Control of Access) Regulations 1993 (S.I. 1993/746) Prevention of Terrorism (Temporary Provisions) Act 1989 (Continuance) Order 1993 (S.I. 1993/747) Combined Probation Areas (Northumbria) Order 1993 (S.I. 1993/748) Combined Probation Areas (Staffordshire) Order 1993 (S.I. 1993/749) Combined Probation Areas (Surrey) Order 1993 (S.I. 1993/750) Medicines Control Agency Trading Fund Order 1993 (S.I. 1993/751) Bingo Duty (Exemptions) Order 1993 (S.I. 1993/752) Finance Act 1989, section 158(1) and (2), (Appointed Days) Order 1993 (S.I. 1993/753) Finance Act 1989, section 178(1), (Appointed Day) Order 1993 (S.I. 1993/754) Income Tax (Indexation) Order 1993 (S.I. 1993/755) Personal Equity Plan (Amendment) Regulations 1993 (S.I. 1993/756) Retirement Benefits Schemes (Indexation of Earnings Cap) Order 1993 (S.I. 1993/757) Taxes (Interest Rate) (Amendment No. 2) Regulations 1993 (S.I. 1993/758) Inheritance Tax (Indexation) Order 1993 (S.I. 1993/759) Capital Gains Tax (Annual Exempt Amount) Order 1993 (S.I. 1993/760) Value Added Tax (Accounting and Records) (Amendment) Regulations 1993 (S.I. 1993/761) Value Added Tax (Cash Accounting) (Amendment) Regulations 1993 (S.I. 1993/762) Value Added Tax (Education) Order 1993 (S.I. 1993/763) Value Added Tax (General) (Amendment) (No. 2) Regulations 1993 (S.I.
Sources: en.wikipedia.org
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.
REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.
Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.